Revolutionizing Drug Discovery AI-Driven Approaches to Personalized Medicine and Predictive Therapeutics
Bibliographic record
Abstract
By discovering and creating novel drugs to treat a range of illnesses, the discipline of drug discovery and development plays a vital role in healthcare. Conventional approaches to drug development have been costly, time-consuming, and frequently produce drugs that don't work for every patient. Precision medicine, on the other hand, seeks to customize medical care to each patient's unique needs while accounting for lifestyle, environment, and genetics. Artificial Intelligence (AI) has revolutionized drug discovery and development in recent years when it has become a potent instrument. Machine learning and deep learning are two examples of AI technologies that could drastically speed up medication discovery, lower prices, and increase treatment efficacy. Researchers can find possible therapeutic targets, create new compounds, and forecast patient response to treatment with the use of artificial intelligence (AI), which analyzes vast datasets and find patterns. This research investigates how AI can be used to find and produce drugs for precision medicine. With adding that, it gives a summary of the conventional drug discovery procedure, emphasizing its drawbacks. Later this research describes how AI technologies are being applied to solve these obstacles, with particular attention to how they are being employed in clinical trials, target identification and validation, and computational drug design. The research also looks at how AI may help to provide personalized medicine, in which each patient receives a customized course of therapy. In summary, this study attempts to present a thorough analysis of the state of AI-driven drug development today and how it can revolutionize precision medicine. Understanding the developments and difficulties in this field helps us to better grasp how AI may transform healthcare in the future and enhance patient outcomes.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.009 | 0.013 |
| Meta-epidemiology (narrow) | 0.001 | 0.001 |
| Meta-epidemiology (broad) | 0.002 | 0.001 |
| Bibliometrics | 0.003 | 0.003 |
| Science and technology studies | 0.001 | 0.005 |
| Scholarly communication | 0.006 | 0.009 |
| Open science | 0.002 | 0.003 |
| Research integrity | 0.002 | 0.006 |
| Insufficient payload (model declined to judge) | 0.004 | 0.002 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".